An attempt was made to use a 2.25x 34mm resolute onyx coronary drug eluting stent to treat a dissection in the diagonal branch that occurred during a procedure performed to treat a moderately tortuous and moderately calcified lesion in the ostium of left anterior descending (lad) artery.The device was inspected with no issues noted.Negative prep was performed with no issues noted.Two wires were in use, one in the lad and another in the diagonal branch.An optical coherence tomography (oct) was performed when a fibrofatty plaque and a luminal narrowing mla of 2.72 mm2 were identified.The device passed through a previously deployed stent.Excessive force was not used during delivery of the device.The lad was pre-dilated with a non-medtronic cutting balloon and a 3x28mm non-medtronic stent was deployed.It was reported that after stenting, the diagonal branch become occluded.A 1.5x15 non-medtronic balloon was used but could not cross, then another non-medtronic 1x5mm balloon was used causing a dissection.The resolute onyx drug eluting stent was then used to treat the dissection when a stent dislodgement occurred during delivery.The stent got stuck in the lad and in the left main.A non medtronic 1x5mm balloon was inflated inside the stent.It was also reported that when attempting to remove it, the stent was displaced from the balloon and got stuck in the profunda femoris branch of the femoral artery.The dislodged stent was not removed.No further injury was reported.
|
Medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
|